Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Positive Topline Results From Phase 2a Pharmacokinetic Trial With Lead Compound FX006 View HTML
Toggle Summary Flexion Therapeutics Announces Changes to Board of Directors View HTML
Toggle Summary Flexion Therapeutics to Present at Wells Fargo Securities Research, Economics & Strategy 2014 Healthcare Conference View HTML
Toggle Summary Flexion Therapeutics to Present at the 2014 Jefferies Healthcare Conference View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2014 Financial Results View HTML
Toggle Summary Flexion Therapeutics to Report First Quarter 2014 Financial Results on May 8, 2014 View HTML
Toggle Summary Flexion Therapeutics Initiates a Phase 2b Confirmatory Dose-Ranging Trial With Lead Compound FX006
Multi-Center Trial Will Enroll Approximately 300 Patients in the U.S. for the Treatment of Pain Associated With Osteoarthritis (OA) of the Knee
View HTML
Toggle Summary Flexion Therapeutics to Present at the 13th Annual Needham Healthcare Conference View HTML
Toggle Summary Flexion Reports Year-End 2013 Financial Results View HTML
Toggle Summary Flexion Therapeutics to Report Year-End 2013 Earning Results on March 27, 2014 View HTML